Barclays Remains a Buy on Medtronic (MDT)
In a report released today, Matt Miksic from Barclays reiterated a Buy rating on Medtronic (MDT – Research Report), with a price target ...
Medtronic to announce financial results for its second quarter of fiscal year 2025
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2025 on Tuesday 19, 2024. A news release ...
Nasdaq9d
Medtronic to announce financial results for its second quarter of fiscal year 2025
A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https://news.medtronic.com. The news release will include summary financial ...
Endovascular Today18d
Medtronic’s Symplicity Spyral RDN Evaluated at 2 Years in SPYRAL HTN-ON MED
Medtronic announced new long-term data from the SPYRAL HTN-ON MED clinical trial of the company’s Symplicity Spyral renal ...
Endovascular Today14d
CMS Grants TPT Payment for Medtronic’s Symplicity Spyral RDN and Recor’s Paradise uRDN Systems
Medtronic and Recor Medical, Inc. (and its parent company, Otsuka Medical Devices Co., Ltd.) separately and independently ...
Nasdaq21d
A new paradigm in electrophysiology: Medtronic receives FDA approval of Affera™ Mapping and Ablation System and Sphere-9™ Catheter
"This marks an exciting milestone for the field, with Medtronic's robust innovation pipeline poised to drive continued progress." "At Medtronic, we have a 75-year tradition of bringing disruptive ...